Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: exixi who wrote (1585)	8/26/2005 3:34:29 PM
From: Icebrg	Respond to of 1826

MGI Pharma "outperform," target price raised Friday, August 26, 2005 12:30:44 PM ET RBC Capital Markets NEW YORK, August 26 (newratings.com) - Analyst David Bouchey of RBC Capital Markets reiterates his "outperform" rating on MGI Pharma (MOGN.NAS). The target price has been raised from $30 to $35. In a research note published this morning, the analyst mentions that the company is expected to win the US FDA approval for its Dacogen drug during next week. The analyst believes that MGI Pharma would begin marketing Dacogen in Europe during 2Q06. RBC Capital Markets adds that Dacogen is expected to significantly contribute to MGI Pharma’s revenues and earnings potential going forward.